Sign in Subscribe
Pharmaceutical industry

GlaxoSmithKline Acquires ID Biomedical Corp. in Definitive Agreement Valued at $1.4 Billion

Strategic Insights

— 2 min read

GlaxoSmithKline (GSK) has agreed to acquire ID Biomedical Corp. (IDBE) in a definitive deal worth approximately $1.4 billion. ID Biomedical, a Canadian biotechnology company, specializes in the development and manufacturing of vaccine products, including influenza vaccines. The acquisition reflects GSK's commitment to address the global public health need for increased supply of influenza vaccines.

As part of the agreement, ID Biomedical's shareholders will receive $35 per share, representing a 13% premium over the closing price on September 6, 2005, and a 30% premium over the 20-day average share price. Additionally, GSK will assume responsibility for ID Biomedical's net debt of $77 million at June 30, 2005. ID Biomedical will become a wholly owned subsidiary of GSK.

The acquisition is subject to the approval of ID Biomedical's shareholders, applicable regulatory clearances, and certain other conditions. The transaction is expected to close by the end of 2005 or early 2006. GSK's vaccines division, led by President Jean Stephenne, sees the deal as a significant step in addressing the pandemic flu threat and enhancing their vaccine presence in the US market.

Key Takeaways:

  • GSK's acquisition of ID Biomedical Corp. is a definitive deal valued at approximately $1.4 billion.
  • ID Biomedical, a Canadian biotechnology company, specializes in the development and manufacturing of vaccine products, including influenza vaccines.
  • The acquisition reflects GSK's commitment to address the global public health need for increased supply of influenza vaccines.
  • ID Biomedical's shareholders will receive $35 per share, representing a 13% premium over the closing price on September 6, 2005, and a 30% premium over the 20-day average share price.
  • GSK will assume responsibility for ID Biomedical's net debt of $77 million at June 30, 2005.
  • ID Biomedical will become a wholly owned subsidiary of GSK.
  • The acquisition is subject to the approval of ID Biomedical's shareholders, applicable regulatory clearances, and certain other conditions.
  • The transaction is expected to close by the end of 2005 or early 2006.
  • GSK's vaccines division will leverage ID Biomedical's expertise and portfolio to enhance their vaccine presence in the US market.

Statistics:

  • The acquisition value is approximately $1.4 billion (US$1.4 billion).
  • The price per share is $35.
  • The deal represents a 13% premium over the closing price on September 6, 2005.
  • The deal represents a 30% premium over the 20-day average share price.
  • ID Biomedical's net debt is $77 million at June 30, 2005.
  • The transaction is expected to close by the end of 2005 or early 2006.

Sources:

  • GlaxoSmithKline plc (GSK)
  • ID Biomedical Corp. (IDBE)
  • Health & Medicine Week editors via NewsRx.com
  • UBS (financial advisor to ID Biomedical on this transaction)
  • Rothschild (financial advisor to GSK on this transaction)

Read more